HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars- Sinai Medical Center, Los Angeles, CA, USA.
Int J Immunogenet. 2020 Jun;47(3):235-242. doi: 10.1111/iji.12494. Epub 2020 May 19.
Organ transplantation is an effective way to treat end-stage organ disease. Extending the graft survival is one of the major goals in the modern era of organ transplantation. However, long-term graft survival has not significantly improved in recent years despite the improvement of patient management and advancement of immunosuppression regimen. Antibody-mediated rejection is a major obstacle for long-term graft survival. Donor human leucocyte antigen (HLA)-specific antibodies were initially identified as a major cause for antibody-mediated rejection. Recently, with the development of solid-phase-based assay reagents, the contribution of non-HLA antibodies in organ transplantation starts to be appreciated. Here, we review the role of most studied non-HLA antibodies, including angiotensin II type 1 receptor (AT R), K-α-tubulin and vimentin antibodies, in the solid organ transplant, and discuss the possible mechanism by which these antibodies are stimulated.
器官移植是治疗终末期器官疾病的有效方法。延长移植物的存活时间是器官移植现代时代的主要目标之一。然而，尽管患者管理得到改善和免疫抑制方案得到推进，近年来长期移植物的存活时间并没有显著改善。抗体介导的排斥反应是长期移植物存活的主要障碍。供体人类白细胞抗原（HLA）特异性抗体最初被确定为抗体介导排斥反应的主要原因。最近，随着基于固相的检测试剂的发展，非 HLA 抗体在器官移植中的作用开始得到重视。在这里，我们综述了最具研究价值的非 HLA 抗体，包括血管紧张素 II 型 1 受体（AT R）、K-α-微管蛋白和波形蛋白抗体，在实体器官移植中的作用，并讨论了这些抗体被刺激的可能机制。
